1986 Fiscal Year Final Research Report Summary
Study of activated carbon adsorbing anticancer drugs for chemotherapy of lymphnode metastasis and peritoneal metastasis.
Project/Area Number |
59870042
|
Research Category |
Grant-in-Aid for Developmental Scientific Research
|
Allocation Type | Single-year Grants |
Research Field |
General surgery
|
Research Institution | Kyoto Prefectural University of Midicine (1985-1986) Akita University (1984) |
Principal Investigator |
TAKAHASHI Toshio Kyoto Prefectural University of Medicine, 医学部, 教授 (50079828)
|
Co-Investigator(Kenkyū-buntansha) |
YAMANE Tetsuro Kyoto Prefectural University of Medicine, 第一外科学教室, 助手 (50166766)
YAMAGUCHI Toshiharu Kyoto Prefectural University of Medicine, 第一外科学教室, 助手 (90111327)
SAKITA Masakazu Kyoto Prefectural University of Medicine, 第一外科学教室, 講師 (40117883)
|
Project Period (FY) |
1984 – 1986
|
Keywords | activated carbon / anticancer drug / lymphnode metastasis / cancerous peritonitis / 腹膜播種性転移 |
Research Abstract |
In this project new drug dosage form "activated carbon adsorbing anticancer drug" was produced. Activated carbon has numerous microposes that possesses great surface area and can adsorb or desorb the drug on the surface. When it is injected into tissues, it is adsorbed into the lymphatic capillaries and immediately reaches the regional lymph nodes. When it is injected into a cancerous pleural or abdominal cavity, it is adsorbed on cancer and serosal surface. Using these properties of the activated carbon, we have prepared activated carbon adsorbing Mitomycin C (MMC-CH) or Adriamicin (ADM-CH) for chemotherapy of lymphnodes metastasis and peritoneal metastasis. Animal experiments revealed that activated carbon adsorbing MMC or ADM was very effective on lymphnode metastasis and pleural or peritoneal metastasis. MMC-CH and ADM-CH were applied to the patients with carcinoma of the stomach, breast and colon for the treatment of lymphnode metastasis. Beside the chemotherapy of lymphnode metastasis, lymphnodes stained in black by activated carbon were easily identified by surgeons,and many lymphnodes were dissected. Forty five of 73 patients with carcinomatous peritonitis responded to MMC-CH. No serious adverse effect was observed. As a result, activated carbon adsorbing anticancer drug was very useful for chemotherapy of lymphnode metastasis and pleural or peritoneal metastasis.
|
Research Products
(12 results)